Explore professionally built ETF model portfolios. Discover now →

Advertisement
Advertisement

iShares Neuroscience and Healthcare ETF

This ETF provides exposure to Equities

IBRN performance and flow charts

Last update 10/16/2026 at 1:30 PM
Live
Closed
Last price
$29.97
-$0.75 (-2.43%) 10/16/2026

Performance

-15.0-10.0-5.00.0%Sep 16Sep 23Sep 30Oct 7Oct 14

Flows

0
1 day price range
$29.97
$30.19
52 week price range
$27.98
$40.65
1W perf
-5.85%
YTD perf
-7.37%
YTD flows
+$2M
AuM
$6M
E/R
0.47%
TTM yield
1.07%
Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

Historic performance and flows

Data as of October 16, 2026
1M3MYTD1Y3Y5Y
Perf.-16.95%-19.96%-7.37%+4.69%+45.93%
Flows-+$2M+$2M+$2M+$759K-
Data as of October 16, 2026
Advertisement

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Characteristics

The iShares Neuroscience and Healthcare ETF is built to track the NYSE FactSet Global Neuro Biopharma and MedTech Net Index - USD. This ETF provides physical exposure - by owning its shares you earn the return of the securities composing the index (as the ETF holds them directly). This share class generates a stream of income by distributing dividends.

Management strategyPassive
StrategyLong Only
ProvideriShares
N° of holdings69
Replication methodDirect (Physical)
Asset classEquity
Dividend policyDistributing
Trailing 12m distribution yield
Join for free
Inception dateAugust 24, 2022
ESGNo
TrackinsightTrackinsight

More data and info about IBRN on Trackinsight

Exposure

Data as of August 31, 2026

Diversification

62.03%

Total weight of top 15 holdings out of 69

Top 15 Holdings

Praxis Precision Medicines, Inc.
5.21%
Dianthus Therapeutics, Inc.
4.96%
ACADIA Pharmaceuticals, Inc.
4.93%
Scholar Rock Holding Corp.
4.85%
Xenon Pharmaceuticals, Inc.
4.4%
argenx SE
4.37%
Arrowhead Pharmaceuticals, Inc.
4.26%
Biogen, Inc.
4.19%
Alkermes Plc
4.15%
PTC Therapeutics, Inc.
3.7%
Denali Therapeutics, Inc.
3.56%
Neurocrine Biosciences, Inc.
3.55%
Dyne Therapeutics, Inc.
3.38%
Edgewise Therapeutics, Inc.
3.3%
Axsome Therapeutics, Inc.
3.23%

Sectors

Healthcare
99.86%
Other
0.14%

Countries

USA
73.41%
Other
26.59%
Advertisement

Trading data

Last sale
10/16/2026 at 1:30 PM
$29.97
Previous close
$30.72
Consolidated volume
10/15/2026
Join for free
Average volume
30 days
Join for free
Average discount or premium
30 days
Join for free
Average Bid/Ask spread
30 days
Join for free

Volatility and drawdown

3M1Y3Y5Y
Volatility+25.01%+26.48%+25.41%
Max drawdown
-26.38%-26.38%-34.98%
Max drawdown duration
58d58d338dN/A
Time to recover
N/AN/A191dN/A

Replication quality

Data as of September 30, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free
Tracking error
Join for free
Tracking difference
Join for free
1 year cumulative return difference
Best
Join for free
Worst
Join for free
daily return difference
Average
Join for free
Worst
Join for free
Advertisement
Frequently asked questions about IBRN

What type of ETF is IBRN?

IBRN is a Passive ETF that provides exposure to Equity assets. It is managed by iShares.

What index does IBRN track?

IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Net Index - USD, aiming to replicate its performance through optimized sampling.

What does IBRN invest in?

This ETF provides exposure to Equities. It is part of the segment: Healthcare Technology.

What is the expense ratio of IBRN?

The total expense ratio (TER) of IBRN is 0.47%, representing the annual fee charged by the fund manager.

When was IBRN launched?

IBRN was launched on August 24, 2022, marking its entry into the ETF market.

Who is the issuer of IBRN?

IBRN is issued by iShares.

What is the AUM of IBRN?

As of October 16, 2026, IBRN manages $5.99 M, reflecting the total assets held in the fund.

How has IBRN performed recently?

As of October 16, 2026, IBRN delivered a return of -16.95% over the past month (1M performance), -19.96% over the past three months (3M), and -7.37% year-to-date (YTD).

Does IBRN pay dividends?

As of October 16, 2026, IBRN has a trailing 12-month distribution yield of 1.07%.

How many holdings are in IBRN

As of August 31, 2026, IBRN holds 69 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.

How diversified is IBRN?

As of August 31, 2026, IBRN holds 69 securities, with 62.03% of its assets concentrated in its top 15 holdings.

What are the top holdings of IBRN?

As of August 31, 2026, IBRN holds a portfolio of 69 underlyings, with its largest positions including Praxis Precision Medicines, Inc., Dianthus Therapeutics, Inc. and ACADIA Pharmaceuticals, Inc.. These top holdings play a significant role in shaping the fund’s performance and exposure.

What countries or regions does IBRN invest in?

As of August 31, 2026, IBRN has its largest geographic exposures in USA.

What sectors or themes does IBRN focus on?

As of August 31, 2026, IBRN is primarily exposed to Healthcare.

The ETF Institute® is now affiliated with ETF Central

The CETF certification is the only FINRA listed professional designation focused on ETFs.

ETF Institute
Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides
Advertisement

Recent educational content

Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs October 5, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · October 6, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 28, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 29, 2026
Tidal ETF Industry KPIs

ETF Trends

ETF Industry KPIs September 22, 2026

This week’s KPI data overview highlights key metrics and trends shaping the ETF landscape.

Tidal
By Tidal · September 23, 2026
First Look ETF September

First Look ETF

First Look ETF: Income, Corporate Arbitrage, and Growth and Value Investing

First Look ETF September 2026: iCapital, Mast Investments and North Square unpack new ETFs targeting monthly income, merger arbitrage and complementary growth and value exposure.

ETF Guide
By ETF Guide · September 23, 2026

Browse all educational columns

Advertisement
ETF Comparison Tool

Have you tried our ETF Compare tool?

Compare ETFs like a pro. Analyze fees, performance, exposure & holdings side-by-side.